Ask the expert: Early-stage hormone receptor-positive, HER2-positive, and triple-positive breast cancer

Tamoxifen is a type of hormonal therapy called a SERM, or selective estrogen receptor modulator, a medicine that prevents estrogen signals from getting to breast cancer cells.

Read More

 | 11 Min. Read |  4

Learn more about hormone receptor-positive metastatic breast cancer, which means the stage IV breast cancer is hormone-sensitive.

Read More

 | 6 Min. Read |  1

Hormone receptor-positive, or HR-positive, breast cancer grows in response to the hormones estrogen and progesterone. These hormones occur naturally in the body and prompt cell action in different ways.

Read More

 | 15 Min. Read |  3

Hormonal therapy medicines are put into classes based on how they interact with the body’s natural hormones estrogen and progesterone. Some stop the body from making estrogen, while others prevent estrogen from helping the cancer cell grow.

Read More

 | 6 Min. Read |  3

Targeted therapies are treatments that target specific proteins or markers on or within cancer cells that help cancer cells grow. There are many different kinds of targeted therapy. Hormonal therapy is a type of targeted therapy because it targets hormones that are active in cancer growth.

Ribociclib (Kisqali), a targeted therapy, is the second CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

Read More

 | 6 Min. Read |  1

Abemaciclib (Verzenio) is a targeted therapy approved by the Food and Drug Administration to treat hormone receptor-positive breast cancer.

Palbociclib (Ibrance), a targeted therapy, was the first CDK 4/6 inhibitor to be approved by the FDA. It targets two specific kinases, or enzymes, that help tumor cells grow and divide.

Read More

 | 5 Min. Read |  3

Elacestrant (Orserdu) is a hormonal therapy used to treat metastatic breast cancer.

Read More

 | 5 Min. Read |  6

Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate, a treatment that pairs a chemotherapy medicine with a targeted therapy. It is approved to treat people diagnosed with metastatic, triple-negative breast cancer and people diagnosed with metastatic breast cancer that is hormone receptor-positive and HER2-negative.

Read More

 | 5 Min. Read |  8